Literature DB >> 8769373

Receptor-specific somatostatin analogs: correlations with biological activity.

D H Coy1, J E Taylor.   

Abstract

A number of cyclic and linear somatostatin (SRIF) analogs have now been found to have promising levels of selectivity for rodent somatostatin receptors (rsst2,3,5), but not sst1 and sst4. Comparisons between binding affinities for these and transfected human receptors are just beginning to emerge and we present results from a comparison of affinities of several key families of peptides for sst2 present on rat AR42J cells and on cells transfected with human (h)sst2. The typical cyclic octapeptide analogs, octreotide, lanreotide, and RC-160, exhibited similar affinities to SRIF for rsst2, but somewhat lower affinities for the human receptor. Affinities of several analogs for transfected hsst5 were also measured. As with the rat receptor, octreotide-related analogs had low affinity for hsst5. The highly specific rsst5 analog, DC-23-99, was less so for the human receptor; however, a D-Tyr1 version of DC-23-99 had subnanomolar affinity (Ki, 0.68 nmol/L) and high selectivity. A new extended-ring analog, BIM-23268D, showed superior affinity to DC-23-99 and even to SRIF and SRIF-28 for hsst5 (K(i), 0.38 nmol/L), and had the highest sst5/sst2 selectivity ratio of any analog that we have tested thus far.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769373     DOI: 10.1016/s0026-0495(96)90073-6

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  Modulation of nuclear internalization of Tat peptides by fluorescent dyes and receptor-avid peptides.

Authors:  Duanwen Shen; Kexian Liang; Yunpeng Ye; Elizabeth Tetteh; Samuel Achilefu
Journal:  FEBS Lett       Date:  2007-04-04       Impact factor: 4.124

Review 2.  Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

3.  Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

Authors:  I Shimon; J E Taylor; J Z Dong; R A Bitonte; S Kim; B Morgan; D H Coy; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

4.  Somatostatin enhances cAMP-dependent short-circuit current in human colon via somatostatin receptor subtype-2.

Authors:  N Hope; G Butt; I Ross; G Warhurst; M Arn; M Grigor; R Lubcke; G O Barbezat
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

5.  Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

Authors:  I Shimon; X Yan; J E Taylor; M H Weiss; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

Review 6.  Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.

Authors:  Ilan Shimon
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

7.  Somatostatin in inflammatory bowel disease.

Authors:  J D van Bergeijk; J H Wilson
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

8.  Meta-analysis on the effects of octreotide on tumor mass in acromegaly.

Authors:  Andrea Giustina; Gherardo Mazziotti; Valter Torri; Maurizio Spinello; Irene Floriani; Shlomo Melmed
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.